2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original ResearchKetamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
Krystal J, Kavalali E, Monteggia L. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology 2023, 49: 41-50. PMID: 37488280, PMCID: PMC10700627, DOI: 10.1038/s41386-023-01629-w.Peer-Reviewed Original ResearchConceptsMood disordersEffective treatmentN-methyl-D-aspartate receptorsGlutamatergic N-methyl-D-aspartate receptorRapid antidepressant effectsTreatment-resistant depressionKey clinical aspectsRapid antidepressant actionsNovel effective treatmentsSynaptic signaling mechanismsMore effective treatmentsSynaptic plasticity mechanismsOpen channel blockerAntidepressant actionAntidepressant effectsKetamine effectsChannel blockersClinical aspectsClinical practiceNew treatmentsNeuropsychiatric disordersCircuit mechanismsDisordersTreatmentKetamine
2022
Technology and Mental Health: State of the Art for Assessment and Treatment
Harvey PD, Depp CA, Rizzo AA, Strauss GP, Spelber D, Carpenter LL, Kalin NH, Krystal JH, McDonald WM, Nemeroff CB, Rodriguez CI, Widge AS, Torous J. Technology and Mental Health: State of the Art for Assessment and Treatment. American Journal Of Psychiatry 2022, 179: 897-914. PMID: 36200275, DOI: 10.1176/appi.ajp.21121254.Peer-Reviewed Original ResearchConceptsHigh-quality evidenceEcological momentary assessmentTechnology-based interventionsMental health applicationsClinical trialsTreatment strategiesCognitive trainingFunctional capacityDrug AdministrationSystematic reviewVirtual reality approachMomentary assessmentU.S. FoodMental healthFunctional skillsTechnology-based assessmentInterventionTechnology-based approachesTreatmentAssessmentHealth applicationsPhysiological parametersReality approachReviewEmotions
2021
STRONG STAR and the Consortium to Alleviate PTSD: Shaping the future of combat PTSD and related conditions in military and veteran populations
Peterson AL, Young-McCaughan S, Roache JD, Mintz J, Litz BT, Williamson DE, Resick PA, Foa EB, McGeary DD, Dondanville KA, Taylor DJ, Wachen JS, Fox PT, Bryan CJ, McLean CP, Pruiksma KE, Yarvis JS, Niles BL, Abdallah CG, Averill LA, Back SE, Baker MT, Blount TH, Borah AM, Borah EV, Brock MS, Brown LA, Burg MM, Cigrang JA, DeBeer BB, DeVoe ER, Fina BA, Flanagan JC, Fredman SJ, Gardner CL, Gatchel RR, Goodie JL, Gueorguieva R, Higgs JB, Jacoby VM, Kelly KM, Krystal JH, Lapiz-Bluhm MD, López-Roca AL, Marx BP, Maurer DM, McDevitt-Murphy ME, McGeary CA, Meyer EC, Miles SR, Monson CM, Morilak DA, Moring JC, Mysliwiec V, Nicholson KL, Rauch SAM, Riggs DS, Rosen CS, Rudd MD, Schobitz RP, Schrader CC, Shinn AM, Shiroma PR, Sloan DM, Stern SL, Strong R, Vannoy SD, Young KA, Keane TM. STRONG STAR and the Consortium to Alleviate PTSD: Shaping the future of combat PTSD and related conditions in military and veteran populations. Contemporary Clinical Trials 2021, 110: 106583. PMID: 34600107, DOI: 10.1016/j.cct.2021.106583.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderCombat posttraumatic stress disorderVeterans AffairsCombat-related posttraumatic stress disorderPublic health advancesPsychological healthVA National CenterResearch ConsortiumVeteran populationRelated conditionsStress disorderHealth advancesNational InstituteTrauma-related researchMilitary personnelPreventionTreatmentInvestigatorsNational CenterHealthDepartmentCollaborative research modelDiagnosisPsychotherapy-supported MDMA treatment for PTSD
Krystal JH, Kelmendi B, Petrakis IL. Psychotherapy-supported MDMA treatment for PTSD. Cell Reports Medicine 2021, 2: 100378. PMID: 34467253, PMCID: PMC8385322, DOI: 10.1016/j.xcrm.2021.100378.Peer-Reviewed Original ResearchArtificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom
Lee EE, Torous J, De Choudhury M, Depp CA, Graham SA, Kim HC, Paulus MP, Krystal JH, Jeste DV. Artificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2021, 6: 856-864. PMID: 33571718, PMCID: PMC8349367, DOI: 10.1016/j.bpsc.2021.02.001.Peer-Reviewed Original ResearchConceptsMental health careMental illnessHealth careMental health care providersHigh-risk individualsHealth care providersElectronic health recordsHigh morbiditySound careStudy groupAmerican CollegeCare providersPsychiatric disordersOwn careProdromal stageClinical diagnosisBrain imagingHealth recordsIllnessCareClinical applicationHealth care fieldIllustrative publicationsTreatmentNeurobiological research
2020
A New Rapid-Acting Antidepressant
Krystal JH, Charney DS, Duman RS. A New Rapid-Acting Antidepressant. Cell 2020, 181: 7. PMID: 32243798, DOI: 10.1016/j.cell.2020.02.033.Peer-Reviewed Original Research
2018
Predicting Barriers to Treatment for Depression in a U.S. National Sample: A Cross-Sectional, Proof-of-Concept Study
Chekroud AM, Foster D, Zheutlin AB, Gerhard DM, Roy B, Koutsouleris N, Chandra A, Esposti MD, Subramanyan G, Gueorguieva R, Paulus M, Krystal JH. Predicting Barriers to Treatment for Depression in a U.S. National Sample: A Cross-Sectional, Proof-of-Concept Study. Psychiatric Services 2018, 69: 927-934. PMID: 29962307, PMCID: PMC7232987, DOI: 10.1176/appi.ps.201800094.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCross-Sectional StudiesDepressive DisorderFemaleHealth Services AccessibilityHumansLogistic ModelsMaleMiddle AgedPatient Acceptance of Health CarePrimary Health CareProof of Concept StudyPsychotherapySampling StudiesSelf-AssessmentSurveys and QuestionnairesTreatment RefusalUnited StatesYoung AdultConceptsDiagnosis of depressionHealth care providersSelf-report survey itemsImplementation of interventionsDerivation cohortUntreated depressionCare providersEffective treatmentU.S. national sampleDrug useDepressionDiagnosisTreatmentU.S. National SurveyPatientsCohortNational surveyNational sampleConcept studySurvey itemsBalanced accuracyIndividualsRetention rateIndependent responsesPrevalence
2017
Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic
Krystal JH, Abdallah CG, Averill LA, Kelmendi B, Harpaz-Rotem I, Sanacora G, Southwick SM, Duman RS. Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic. Current Psychiatry Reports 2017, 19: 74. PMID: 28844076, PMCID: PMC5904792, DOI: 10.1007/s11920-017-0829-z.Peer-Reviewed Original ResearchConceptsSynaptic connectivityRapid-acting treatmentPathophysiology of PTSDPotential clinical importanceTreatment of PTSDSynaptic lossPurpose of ReviewStudiesDisconnection syndromeClinical importanceNovel pharmacotherapeuticsNovel therapeuticsPTSD symptomsRecent FindingsHerePTSDPathophysiologyKetamineTreatmentDisordersTherapeutic applicationsStress-related lossesSyndromeSymptomsPharmacotherapeutics
2016
PTSD: from neurobiology to pharmacological treatments
Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. PTSD: from neurobiology to pharmacological treatments. European Journal Of Psychotraumatology 2016, 7: 31858. PMID: 27837583, PMCID: PMC5106865, DOI: 10.3402/ejpt.v7.31858.Peer-Reviewed Original ResearchPosttraumatic stress disorderPharmacological treatmentPathophysiology of PTSDFirst-line pharmacotherapyMultiple neurobiological systemsEtiology of PTSDFull remissionTherapeutic effectPsychiatric disordersPharmacologic targetStress disorderNeurobiological systemsPathophysiologyFuture targetsTreatmentTraumatic eventsDisordersRemissionPharmacotherapyEtiologyInjurySymptomsYearsWeeksWhat I have changed my mind about and why
Yehuda R, Spiegel D, Southwick S, Davis LL, Neylan TC, Krystal JH. What I have changed my mind about and why. European Journal Of Psychotraumatology 2016, 7: 33768. PMID: 27837585, PMCID: PMC5106864, DOI: 10.3402/ejpt.v7.33768.Peer-Reviewed Original ResearchField of traumaComprehensive holistic careSocial cuesTrauma exposureMore general principlesIntegrative therapiesCompetitive workRachel YehudaSpecific treatment guidelinesMindTreatment guidelinesEvidence baseHolistic careEffective treatmentVeterans AffairsMindfulnessPTSDIntegrating ClinicalCuesLogotherapyTreatmentIcahn SchoolClear limitationsNovel mechanismKrystal
2009
Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia
Krystal JH, Tolin DF, Sanacora G, Castner SA, Williams GV, Aikins DE, Hoffman RE, D'Souza DC. Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia. Drug Discovery Today 2009, 14: 690-697. PMID: 19460458, PMCID: PMC2898127, DOI: 10.1016/j.drudis.2009.05.002.Peer-Reviewed Original ResearchConceptsPsychiatric disordersSymptomatic reliefMood disordersAnxiety disordersNeuroplasticity deficitsCurrent pharmacotherapyUnderlying abnormalityCurrent treatmentPsychiatric treatmentNeuroplasticityDisordersPharmacotherapyTreatmentExciting new findingsSchizophreniaReliefAbnormalitiesNeurodevelopmentNew findingsPrevention
2008
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Krishnan-Sarin S, O'Malley S, Krystal JH. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Research 2008, 31: 400-7. PMID: 23584013, PMCID: PMC3860468.Peer-Reviewed Original ResearchConceptsAlcohol dependenceCurrent treatment optionsAlcohol-drinking behaviorDifferent neurochemical systemsAdjunctive treatmentModest efficacyTreatment optionsNew medicationsNew pharmacotherapiesMedicationsHealth problemsNeurochemical systemsPharmacotherapyTreatmentGreat needCertain genesNaltrexoneAlcoholismDisulfiramDrinkers
2007
Neurobiology and Treatment of Depression
Neumeister A, Charney D, Sanacora G, Krystal J. Neurobiology and Treatment of Depression. 2007 DOI: 10.1002/9780470101001.hcn018.Peer-Reviewed Original ResearchNeurobiology of depressionTreatment of depressionPotential novel treatment approachesNovel treatment approachesEtiology of depressionAvailable treatmentsDepressed patientsNeuroanatomical disruptionsTreatment approachesNeural circuitsAbstract DepressionNovel targetCurrent conceptsDepressionTreatmentNeurobiological systemsNeurobiologyPatientsPathogenesisEtiologyEnvironmental factors
2006
MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases
Mason GF, Krystal JH. MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases. NMR In Biomedicine 2006, 19: 690-701. PMID: 16986118, DOI: 10.1002/nbm.1080.Peer-Reviewed Original ResearchConceptsPsychiatric diseasesMagnetic resonance spectroscopyGlial abnormalitiesPsychiatric disordersBiochemical markersNon-invasive techniqueNeuropsychiatric disordersPotential roleDrug developmentDrug discoveryMRS techniquesDiseaseDisordersStudy of mechanismsTreatmentLines of investigationAbnormalitiesNeurochemistryDrug delivery
2003
N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability
Krystal JH, Petrakis IL, Mason G, Trevisan L, D'Souza DC. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacology & Therapeutics 2003, 99: 79-94. PMID: 12804700, DOI: 10.1016/s0163-7258(03)00054-8.Peer-Reviewed Original ResearchConceptsGlutamatergic systemEthanol abuseGlutamate receptorsN-methyl-D-aspartate (NMDA) subtypePrimary excitatory neurotransmitterAspartate glutamate receptorsAction of ethanolEthanol withdrawalGlutamatergic agentsGlutamatergic functionExcitatory neurotransmitterTranslational neuroscience perspectiveGlutamate systemEthanol intoxicationBehavioral effectsEthanol contributeAlcoholismBrainReceptorsTreatmentAbuseN-methylSubtypesNeurotransmittersIntoxicationIncreased Cortical GABA Concentrations in Depressed Patients Receiving ECT
Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. Increased Cortical GABA Concentrations in Depressed Patients Receiving ECT. American Journal Of Psychiatry 2003, 160: 577-579. PMID: 12611844, DOI: 10.1176/appi.ajp.160.3.577.Peer-Reviewed Original ResearchConceptsOccipital cortex GABA concentrationsCortical GABA concentrationsCourse of ECTGABA concentrationDepressed patientsConsiderable anticonvulsant effectsSevere refractory depressionGamma-aminobutyric acid concentrationProton magnetic resonance spectroscopyRefractory depressionAnticonvulsant effectsAntidepressant actionGABAergic transmissionECT treatmentGABAergic involvementEffective treatmentECT mechanismsDepressed subjectsPatientsSignificant increaseDepressionTreatmentECTMagnetic resonance spectroscopyAcid concentrationA placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder
Sierra M, Phillips ML, Ivin G, Krystal J, David AS. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. Journal Of Psychopharmacology 2003, 17: 103-105. PMID: 12680746, DOI: 10.1177/0269881103017001712.Peer-Reviewed Original ResearchConceptsDepersonalization disorderEfficacy of lamotrigineWeeks of treatmentCross-over trialCross-over periodCross-over designDSM-IV depersonalization disorderSole medicationGlutamate releaseLamotriginePatientsCambridge Depersonalization ScaleDisordersTreatmentDepersonalization ScalePlaceboMedicationsHyperactivityRespondersTrialsWeeks
2002
Increased Occipital Cortex GABA Concentrations in Depressed Patients After Therapy With Selective Serotonin Reuptake Inhibitors
Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased Occipital Cortex GABA Concentrations in Depressed Patients After Therapy With Selective Serotonin Reuptake Inhibitors. American Journal Of Psychiatry 2002, 159: 663-665. PMID: 11925309, DOI: 10.1176/appi.ajp.159.4.663.Peer-Reviewed Original ResearchConceptsOccipital cortex GABA concentrationsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsGamma-aminobutyric acidGABA concentrationReuptake inhibitorsDepressed patientsMajor depressionMedication-free depressed patientsMonths of treatmentInitiation of treatmentTreatment of depressionCSF of individualsProton magnetic resonance spectroscopyLow GABA concentrationsSSRI medicationAntidepressant actionSSRI treatmentOccipital cortexDepressed subjectsTreatmentDepressionPatientsSignificant increaseCommon mechanismGlutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry 2002, 7: s71-s80. PMID: 11986998, DOI: 10.1038/sj.mp.4001021.Peer-Reviewed Original ResearchConceptsCortical GABA levelsMood-stabilizing treatmentMood disordersGABA levelsΓ-amino-butyric acid (GABA) systemMood-stabilizing agentsGlutamate receptor functionDevelopment of medicationsGABA deficitAvailable antidepressantsGABAergic modulationAntimanic effectsGlutamatergic activityClinical evidenceNovel antidepressantsGABA systemAntidepressant drugsNew agentsReceptor functionAvailable evidenceReceptor targetsAntidepressantsDisordersGlutamateTreatment